Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — ASX SMIDcaps Conference 2026
11 slides from Avecho Biotechnology's conference presentation, Sep 23, 2026
Slide 1: Avecho to present at the ASX SMIDcaps Conference
ASX Announcement 23 September 2026 For personal use only Avecho to present at the ASX SMIDcaps Conference Melbourne, Australia, 23 September 2026: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or “the Company”) is pleased to advise that CEO Dr Paul Gavin will present at the ASX SMIDcaps Conferen
Slide 2: About Avecho's Phase III Trial Program
About Avecho’s Phase III Trial Program The Company is currently conducting a pivotal (Phase III), multi-centre, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of CBD TPM soft-gel capsules in adults for use in the reduction of insomnia severity. The tri
Slide 3: Developing the first pharmaceutical cannabidiol product for insomnia
ASX SMIDcaps Conference September 2026 rsonal use only Developing the first pharmaceutical cannabidiol product for insomnia www.avecho.com.au | ASX:AVE
Slide 4: Safe Harbour Statement
This presentation, and any differences may be material representations made before, during (whether positive or negative). or after the presentation, may The risks that may cause Avecho‘s Safe Harbour include forward-looking statements actual results, performance or rsonal use only that are inherent
Slide 5: Company Snapshot: Where Avecho sits today
COMPANY SNAPSHOT Where Avecho sits today AVE CORPORATE SUMMARY rsonal use only Proprietary product Shares on issue 3.86 Bn TPM-enhanced synthetic cannabidiol (CBD) capsule; IP protection to ~2043. A registered pharmaceutical, not a medicinal-cannabis product. Cash (end June 2026) A$6.6 M Market capi
Slide 6: Insomnia is a major problem worldwide
Insomnia is a major 10-30% rsonal use only of people across the world problem worldwide1 experience insomnia symptoms Broadly defined as difficulty initiating or maintaining sleep Insomnia market worth Insomnia can be a symptom of a range of other disorders, particularly mental health and psychiatri
Slide 7: Pivotal Phase III Trial passed the interim analysis
THE DE-RISKING EVENT Pivotal Phase III Trial passed the interim analysis rsonal use only UNANIMOUS Independent DMB recommends the trial continue to 519 patients — sample size unchanged EFFICACY · on track? SAFETY · is it tolerable? • By recommending continuation at the original sample size — Approve
Slide 8: The Australian Opportunity
The Australian Opportunity rsonal use only Australia – First Mover Market Licensed to Sandoz – Key Terms2 • A registered CBD medicine can sell over the counter in • Exclusive Australian rights Australia — through pharmacies, no prescription • US$3M upfront — received on signing • No such product is
Slide 9: Completing the trial and the value ahead
THE PLAN FROM HERE Completing the trial — and the value ahead rsonal use only ~320 ~10 sites ~12 months patients to complete to trial completion identified & ready (includes spares) (once all sites open) H2 2026 Recommence Trial 2027 Complete Trial • Pursue further licensing deals • Recommence dosin
Slide 10: Every part of our thesis has been independently validated
CLOSING ARGUMENT Every part of our thesis has been independently validated rsonal use only For years we have claimed big things for this product. At each step, an external body has validated those predictions. One piece of validation remained. US, EU & Japan Preclinical TGA Sandoz Market Interim ana
Slide 11: Questions Welcome
Questions Welcome rsonal use only Dr Paul Gavin Melbourne Office Chief Executive Officer Unit A8, 2A Westall Road T. +61 3 9002 5000 Hallmarc Business Park E. pgavin@avecho.com.au Clayton VIC 3168 Australia T: +61 3 9002 5000 E: info@avecho.com.au